Table 1. Patient characteristics*.
| Age | Average (min.-max) | 59.5 (40–88) |
|---|---|---|
| Number of samples | % | |
| cTumor size | ||
| T1 | 14 | 46.7% |
| T2 | 15 | 50.0% |
| T3 | 1 | 3.3% |
| T4 | 0 | 0.0% |
| cN | ||
| Positive | 0 | 0.0% |
| Negative | 30 | 100.0% |
| ER | ||
| Positive | 30 | 100.0% |
| Negative | 0 | 0.0% |
| PgR | ||
| Positive | 25 | 83.3% |
| Negative | 5 | 16.7% |
| HER2 | ||
| Positive | 0 | 0.0% |
| Negative | 30 | 100.0% |
| Historogical grade | ||
| I | 16 | 53.3% |
| II | 11 | 36.7% |
| III | 2 | 6.7% |
| Unknown | 1 | 3.3% |
| Hormone therapy | ||
| Tamoxifen | 11 | 36.7% |
| Letrozole | 19 | 63.3% |
| Operation | ||
| Total mastectomy | 12 | 40.0% |
| Partial mastectomy | 18 | 60.0% |
Abbreviations: *c: Clinical; ER: Estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor 2.